Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines:: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors

被引:90
作者
Boschelli, DH
Wu, ZP
Klutchko, SR
Showalter, HDH
Hamby, JM
Lu, GH
Major, TC
Dahring, TK
Batley, B
Panek, RL
Keiser, J
Hartl, BG
Kraker, AJ
Klohs, WD
Roberts, BJ
Patmore, S
Elliott, WL
Steinkampf, R
Bradford, LA
Hallak, H
Doherty, AM
机构
[1] Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA
[2] Parke Davis Pharmaceut Res, Dept Canc Res, Ann Arbor, MI 48105 USA
[3] Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[4] Parke Davis Pharmaceut Res, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA
关键词
D O I
10.1021/jm980398y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of 1 with a 4-(N,N-diethylaminoethoxy)phenylamino group yielded 2a, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogues that retained potency, including derivatives that were biased toward inhibition of the TK activity of PDGFr. Analogues of 2a with a 3-thiophene or an unsubstituted phenyl group at C-6 were the most potent inhibitors. Compound 54, which had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, respectively, was active in a variety of PDGF-dependent cellular assays and blocked the in vivo growth of three PDGF-dependent tumor lines.
引用
收藏
页码:4365 / 4377
页数:13
相关论文
共 56 条
[1]   1-oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase [J].
Barvian, MR ;
Panek, RL ;
Lu, GH ;
Kraker, AJ ;
Amar, A ;
Hartl, B ;
Hamby, JM ;
Showalter, HDH .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (22) :2903-2908
[2]  
Bridges AJ, 1996, CURR MED CHEM, V3, P167
[3]   Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].
Bridges, AJ ;
Zhou, H ;
Cody, DR ;
Rewcastle, GW ;
McMichael, A ;
Showalter, HDH ;
Fry, DW ;
Kraker, AJ ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276
[4]   SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS [J].
BUCHDUNGER, E ;
ZIMMERMANN, J ;
METT, H ;
MEYER, T ;
MULLER, M ;
REGENASS, U ;
LYDON, NB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2558-2562
[5]   SYNTHESE ET ACTION DE QUELQUES ANESTHESIQUES LOCAUX DERIVES DE LA PROCAINE [J].
BUCHI, J ;
ENEZIAN, J ;
ENEZIAN, G ;
VALETTE, G ;
PATTANI, C .
HELVETICA CHIMICA ACTA, 1960, 43 (07) :1971-1979
[6]   Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors [J].
Connolly, CJC ;
Hamby, JM ;
Schroeder, MC ;
Barvian, M ;
Lu, GH ;
Panek, RL ;
Amar, A ;
Shen, C ;
Kraker, AJ ;
Fry, DW ;
Klohs, WD ;
Doherty, AM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (18) :2415-2420
[7]  
Dahring TK, 1997, J PHARMACOL EXP THER, V281, P1446
[8]   5,7-DIMETHOXY-3-(4-PYRIDINYL)QUINOLINE IS A POTENT AND SELECTIVE INHIBITOR OF HUMAN VASCULAR BETA-TYPE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR TYROSINE KINASE [J].
DOLLE, RE ;
DUNN, JA ;
BOBKO, M ;
SINGH, B ;
KUSTER, JE ;
BAIZMAN, E ;
HARRIS, AL ;
SAWUTZ, DG ;
MILLER, D ;
WANG, S ;
FALTYNEK, CR ;
XIE, W ;
SARUP, J ;
BODE, DC ;
PAGANI, ED ;
SILVER, PJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (17) :2627-2629
[9]   SIMIAN SARCOMA-VIRUS ONC GENE, V-SIS, IS DERIVED FROM THE GENE (OR GENES) ENCODING A PLATELET-DERIVED GROWTH-FACTOR [J].
DOOLITTLE, RF ;
HUNKAPILLER, MW ;
HOOD, LE ;
DEVARE, SG ;
ROBBINS, KC ;
AARONSON, SA ;
ANTONIADES, HN .
SCIENCE, 1983, 221 (4607) :275-277
[10]  
ELLIOTT WL, 1989, CANCER RES, V49, P5586